Mefloquine anxiety, depression, unusual behavior, and suicidal ideations, among others. Neurologic effects include dizziness, loss of balance, and tinnitus. The label warns that mild symptoms may presage more serious ones, and that the drug should be discontinued at the first sign of symptoms. Mefloquine should not be used in people with a history of psychiatric problems. Central nervous system events requiring hospitalization occur in about one in 10,000 people taking mefloquine for malaria prevention, with milder events (e.g., dizziness, headache, insomnia, and vivid dreams) in up to 25%. When some measure of subjective severity is applied to the rating of adverse
Association for the Treatment of Sexual Abusers 2.926, ranking 5th out of the 58 tracked journals in criminology and penology. The journal typically receives 100-150 manuscript submissions annually from researchers and practitioners in 25-30 countries and has an acceptance rate of approximately 50 percent. Association for the Treatment of Sexual Abusers The Association for the Treatment of Sexual Abusers (ATSA) is an international, multi-disciplinary, non-profit organization dedicated to making society safer by preventing sexual abuse. ATSA promotes sound research, evidence-based practice, informed public policy, and collaborative community strategies that lead to the effective assessment, treatment, and management of individuals who sexually abuse or are at risk to